Distant Metastasis Risk Definition by Tumor Biomarkers Integrated Nomogram Approach for Locally Advanced Nasopharyngeal Carcinoma
暂无分享,去创建一个
Ming Li | Jian Zheng | M. Hong | X. Wan | Jian-jun Xiao | Y. Huang | Xiaobo Guo | Yizhen Yu | Xinjuan Fan | Yarong Xie | Haiyang Chen | Yan Ma | X. Pang | F. He | Shuai Liu | Jian‐jun Xiao
[1] K. Lam,et al. Management of Nasopharyngeal Carcinoma: Is Adjuvant Therapy Needed? , 2018, Journal of oncology practice.
[2] Christine Y. Lu,et al. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014) , 2017, British Journal of Cancer.
[3] T. Gamblin,et al. The prognostic utility of baseline alpha‐fetoprotein for hepatocellular carcinoma patients , 2017, Journal of surgical oncology.
[4] Ji-Jin Yao,et al. Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA , 2017, Cancer science.
[5] Mingyu Liu,et al. Overexpression of N-cadherin and β-catenin correlates with poor prognosis in patients with nasopharyngeal carcinoma. , 2017, Oncology letters.
[6] J. Griggs,et al. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. , 2016, JAMA oncology.
[7] Xinran Tang,et al. Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis , 2016, International journal of molecular sciences.
[8] Rui Sun,et al. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. , 2016, Journal of the National Cancer Institute.
[9] Anne W M Lee,et al. Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Qian,et al. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. , 2015, European journal of cancer.
[11] D. Kannarunimit,et al. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events , 2015, Radiation Oncology.
[12] Li Zhang,et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Baselga,et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Rensheng Wang,et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] H. Ying,et al. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes. , 2014, Oral oncology.
[16] Jian Lu,et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. , 2013, The Lancet. Oncology.
[17] E. Hui,et al. Targeting tumor hypoxia in nasopharyngeal carcinoma , 2013, Head & neck.
[18] R. Sun,et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. , 2012, Oral oncology.
[19] Jie Xu,et al. Aurora‐A activation, correlated with hypoxia‐inducible factor‐1α, promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma , 2012, Cancer science.
[20] Jin-Ching Lin,et al. Current management of nasopharyngeal cancer. , 2012, Seminars in radiation oncology.
[21] A. King,et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. , 2012 .
[22] Y. Huang,et al. Epithelial–mesenchymal transition biomarkers and support vector machine guided model in preoperatively predicting regional lymph node metastasis for rectal cancer , 2012, British Journal of Cancer.
[23] Yan Zhang,et al. Molecular Prognostic Prediction for Locally Advanced Nasopharyngeal Carcinoma by Support Vector Machine Integrated Approach , 2012, PloS one.
[24] A. Garden,et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. , 2012, The Lancet. Oncology.
[25] Jie Xu,et al. Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Jie Xu,et al. Elevated Beclin 1 expression is correlated with HIF-1α in predicting poor prognosis of nasopharyngeal carcinoma , 2010, Autophagy.
[27] Jian-ming Li,et al. Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer , 2010, Cancer biology & therapy.
[28] Jordi Giralt,et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.
[29] Jun Ma,et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] O. Kallioniemi,et al. Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.
[31] Jun Ma,et al. A comparison of the Chinese 1992 and fifth‐edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma , 2000, Cancer.
[32] W. Enker,et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Pelayo Vilar,et al. Nasopharyngeal Carcinoma , 1966 .